| 0.9317 -0.038 (-3.89%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.16  |
1-year : | 1.27 |
| Resists | First : | 0.99 |
Second : | 1.09 |
| Pivot price | 0.95 |
|||
| Supports | First : | 0.83 | Second : | 0.69 |
| MAs | MA(5) : | 0.9 |
MA(20) : | 0.97 |
| MA(100) : | 1.17 |
MA(250) : | 1.66 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 33 |
D(3) : | 20.7 |
| RSI | RSI(14): 43.8 |
|||
| 52-week | High : | 5.94 | Low : | 0.81 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MRKR ] has closed above bottom band by 27.2%. Bollinger Bands are 43.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.97 - 0.98 | 0.98 - 0.98 |
| Low: | 0.9 - 0.91 | 0.91 - 0.91 |
| Close: | 0.9 - 0.91 | 0.91 - 0.92 |
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
Thu, 06 Nov 2025
Marker Therapeutics Strengthens Board with New Appointment - MSN
Wed, 05 Nov 2025
Marker Therapeutics Appoints New Board Member - TradingView
Wed, 05 Nov 2025
Marker Therapeutics Appoints Kathryn Penkus Corzo to Board of Directors - Quiver Quantitative
Wed, 05 Nov 2025
Marker (NASDAQ: MRKR) names Kathryn Penkus Corzo to board effective Nov. 1, 2025 - Stock Titan
Wed, 27 Aug 2025
Marker Therapeutics (MRKR) Falls 20.6% After Positive Clinical Study - Yahoo Finance
Tue, 26 Aug 2025
Marker Therapeutics Stock Drops After Report About Lymphoma Treatment - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 13 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 7 (%) |
| Held by Institutions | 26.3 (%) |
| Shares Short | 286 (K) |
| Shares Short P.Month | 864 (K) |
| EPS | -1.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.93 |
| Profit Margin | -271.2 % |
| Operating Margin | -494.8 % |
| Return on Assets (ttm) | -69.4 % |
| Return on Equity (ttm) | -144.7 % |
| Qtrly Rev. Growth | -26.3 % |
| Gross Profit (p.s.) | -0.81 |
| Sales Per Share | 0.41 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.68 |
| PEG Ratio | 0 |
| Price to Book value | 0.98 |
| Price to Sales | 2.19 |
| Price to Cash Flow | -1.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|